目的 分析2019—2021年安徽醫(yī)科大學(xué)附屬六安醫(yī)院保肝類藥物使用情況以及應(yīng)用趨勢(shì)，旨在為臨床保肝類藥物合理用藥提供參考依據(jù)。方法 回顧性分析安徽醫(yī)科大學(xué)附屬六安醫(yī)院2019年1月—2021年12月年保肝藥類藥物的銷售金額、使用頻度（DDDs）、日均費(fèi)用（DDC）等數(shù)據(jù)進(jìn)行匯總統(tǒng)計(jì)并分析。結(jié)果 2019—2021年保肝類藥物銷售金額總體呈下降趨勢(shì)，其中口服保肝類藥物金額總體變化不大，構(gòu)成比呈增長(zhǎng)趨勢(shì)。抗炎保肝類藥物銷售金額連續(xù)2年位居第1位。熊去氧膽酸膠囊和甘草酸二銨腸溶膠囊DDDs連續(xù)3年位居前3位。注射用門(mén)冬氨酸鳥(niǎo)氨酸、異甘草酸鎂注射液DDC排名連續(xù)3年保持前2位。大部分保肝類藥物B/A值均接近于1，說(shuō)明同步性良好。結(jié)論 安徽醫(yī)科大學(xué)附屬六安醫(yī)院保肝類藥物使用基本合理，符合安全、有效、經(jīng)濟(jì)用藥原則。

Objective To analysis the usage and application trend of hepatoprotective drugs in Lu’an Hospital Affiliated to Anhui Medical University, so as to provide reference basis for the rational use of hepatoprotective drugs. Methods The application data of hepatoprotective drugs in Lu’an Hospital Affiliated to Anhui Medical University from January 2019 to December 2021 were statistically analyzed in terms of total sale amount, defined daily dose system (DDDs), daily drug cost (DDC), the ranking ratio (B/A), and so on. Results From 2019 to 2021, the sales amount of hepatoprotective drugs showed a downward trend, in which the amount of oral liver protection drugs showed little change, and the composition ratio showed an increasing trend. The sales amount of anti-inflammatory and hepatoprotective drugs ranked first for two consecutive years. The DDDs of Ursodeoxycholic Acid Capsules and Diammonium Glycyrrhizinate Enteric-coated Capsules ranked the top three for three consecutive years. DDC of Ornithine Aspartate for Injection and Magnesium Isoglycyrrhizinate Injection ranked the top two for three consecutive years. Most B/A values of hepatoprotective drugs were close to 1, indicating good synchronization. Conclusion The utilization of hepatoprotective drugs in Lu’an Hospital Affiliated to Anhui Medical University is basically reasonable, in line with the medication principles of safe, effective and economic.

R975

安徽高校自然科學(xué)研究項(xiàng)目(KJ2021A0342);安徽醫(yī)科大學(xué)校科研基金項(xiàng)目(2020xkj231)